An Overview of Kancure, LLC

907 views
811 views

Published on

Kancure, LLC is a start-up biotechnology company aiming at the development of an anti-cancer drug treatment for Chronic Myeloid Leukemia, created as part of a mock assignment in the Entrepreneurial Biotechnology course.

1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total views
907
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
12
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

An Overview of Kancure, LLC

  1. 1. Making Cancer More Treatable <ul><li>Company Overview: Ruchi Shah, CEO </li></ul><ul><li>Research and Development: Ramola Chendvankar, CSO </li></ul><ul><li>Marketing and Commercialization: Mridula Shukla, CMO </li></ul><ul><li>Financial Outlook: Jennie McCollum, CFO </li></ul>
  2. 2. Company Overview <ul><li>Start-up Biotechnology Company </li></ul><ul><li>Orphan Drug (4000 people in the US) </li></ul><ul><li>Specializes in the Development of drug against CML: LeukX </li></ul><ul><li>Aims to triumph over the resistance developed towards Gleevec </li></ul><ul><li>Clinical Trials: Phase I </li></ul><ul><li>Expected sales of $ 13M in 2012 </li></ul>
  3. 3. About the Company <ul><li>Company Structure  LLC </li></ul><ul><li>Location  Rockville, MD </li></ul><ul><li>Science Advisory Board  </li></ul><ul><li>Dr. Jack Chirikjian </li></ul><ul><li>Dr. Milton Brown </li></ul><ul><li>Venture Capitalists  $14,000,000 </li></ul><ul><li>Exit Strategy  IPO </li></ul><ul><li>Acquisition </li></ul>
  4. 4. Intellectual property <ul><li>The technology belongs to </li></ul><ul><li>Georgetown University and has </li></ul><ul><li>been patented in 2005 </li></ul><ul><li>Up-front fees: $ 50,000 </li></ul><ul><li>2% of sales </li></ul>TM TM
  5. 5. Chronic Myeloid Leukemia <ul><li>Unregulated growth of Myeloid cells in the body. </li></ul><ul><li>40% people have developed resistance towards drugs available. </li></ul><ul><li>Philadelphia Chromosome </li></ul><ul><li>P210 protein is produced which acts as tyrosine kinase domain. </li></ul><ul><li>Activates series of proteins </li></ul><ul><li>Genetic instability. </li></ul>
  6. 6. Gleevec Ineffectiveness <ul><li>Bcr-Abl gene amplified </li></ul><ul><li>Over expression of the protein. </li></ul><ul><li>Mutations in kinase domain which affects the Gleevec binding. </li></ul><ul><li>Allosteric mutations causing conformational change. </li></ul><ul><li>Ineffective in blast crisis. </li></ul><ul><li>Heart failure in some patients </li></ul>
  7. 7. LeukX <ul><li>Doxorubicin </li></ul><ul><li>Prevents amplifications & replications of Bcr-Abl gene. </li></ul><ul><li>Natural compound B phenyl isothiocyanate . </li></ul><ul><li>Degradation of the over expressed protein. </li></ul><ul><li>Activates transcription factor for the differentiation of proteins in blast crisis stage. </li></ul><ul><li>Heterocyclic compound called 2 phenyl amino pyrimidine that acts as kinase inhibitor. </li></ul><ul><li>Binds to T315I mutated domain </li></ul>
  8. 8. Research studies <ul><li>Compared the efficacy with Imatinib, Disatinib, Nicotinib. </li></ul><ul><li>T315I mutated cell lines were obtained treated with LeukX. </li></ul><ul><li>Binds tightly to the T315I mutated kinase domain. </li></ul><ul><li>Activates transcription factor for differentiation of immature cells in blast crisis stage. </li></ul><ul><li>P210 level compared on electrophoresis </li></ul>
  9. 9. Clinical Research <ul><li>Phase I </li></ul><ul><li>Determine side effects of the LeukX on healthy patients. </li></ul><ul><li>Minimum Side effects. </li></ul><ul><li>Effect on left ventricle of the heart Monitored. </li></ul><ul><li>Phase II & III </li></ul><ul><li>Both Imatinib resistance and imatinib sensitive patients would be tested. </li></ul><ul><li>Different doses of the drug would be administered </li></ul><ul><li>Efficacy would be compared with Gleevec, Sprycel & Tasigna. </li></ul>
  10. 10. Competition Not effective in T315I mutation. Not effective against T3151 mutation. Not effective against T315I mutation. Not effective in Blast crisis. Not Effective in Blast crisis Not effective in Blast crisis 29 million in 2008 142 millions in 2008 1800 millions in 2008 Novartis Bristols-myers Squibs Novartis Tasigna Sprycel Gleevec
  11. 11. Our Product & Patients Our Product & Patients <ul><li>LeukX is a unique treatment for Chronic Myeloid Leukemia (CML). It works by targeting, and turning off, specific proteins in cells that cause the cancer cells to grow and multiply </li></ul><ul><li>CML mostly affects adults, although 2 percent of CML patients are children. </li></ul><ul><li>Kancure would target the patients with normal genes, mutated genes T315I and patients those who are within the age range of 45-80 </li></ul>
  12. 12. Marketing Channels Marketing Channels http:// www.Kancure.com
  13. 13. LeukX Marketing Plan - Stages <ul><li>Completed: Pre-Clinical Trial </li></ul>LeukX Development Timeline Marketing Activity 2009 Phase I <ul><li>Market Research </li></ul><ul><li>Fund Raising </li></ul><ul><li>Managing relations with investors </li></ul>2010 Phase II 2011 Phase III 2012 Product Launch <ul><li>Develop Product Profile </li></ul><ul><li>Research on alternative uses of LeukX </li></ul><ul><li>Plan Brand campaign </li></ul><ul><li>Develop Marketing message </li></ul><ul><li>Start Product Promotion </li></ul><ul><li>Plan Launch Campaign </li></ul><ul><li>Manage sales and distribution </li></ul><ul><li>Product Launch Campaign </li></ul><ul><li>Monitor performance </li></ul>2 Resources 3 Resources 5 Resources 7 resources Marketing Team
  14. 14. LeukX Competitor & Pricing LeukX Price: $30 per 100 mg “ Oncology is the top of the bill when it comes to new products in development..” USA Today – May 2008 CML Drug market was more than $7 billion globally in 2008 Competitor Sales Volume Gleevec 1,800 Million Sprycel 142 Million Tasigna 29 Million
  15. 15. LeukX Sales Forecast <ul><li>Assumptions: </li></ul><ul><li>CML Drug Market was $7 Billion in 2007 </li></ul><ul><li>100% of the sales will be from US Markets in 2012 </li></ul><ul><li>LeukX sales forecast is based on Gleevec sales in the last 4 yrs </li></ul><ul><li>LeukX will capture a conservative 0.22% of Gleevec sales, which is projected to be $5.9 Billion in 2012 </li></ul>LeukX Sales Forecast Year 2012 2013 Sales ($) $ 13 M $ 15 M
  16. 16. SWOT Analysis <ul><li>Strengths </li></ul><ul><li>Effective treatment for CML </li></ul><ul><li>Competitive Pricing </li></ul><ul><li>Weakness </li></ul><ul><li>Early phase development </li></ul><ul><li>Unknown brand </li></ul><ul><li>Opportunity </li></ul><ul><li>Growing Market for Cancer Drug </li></ul><ul><li>Possibility of alliances & collaboration </li></ul><ul><li>Threats </li></ul><ul><li>Competitive Marketplace </li></ul><ul><li>Current market conditions – reduced funding </li></ul>
  17. 17. Sources of Capital
  18. 18. Projected Income Statement
  19. 19. Profit Projection
  20. 20. Break Even Analysis <ul><li>Fixed Costs: $3,635,150 </li></ul><ul><li>Variable Cost (Per Unit): $17 </li></ul><ul><li>Selling Price (Per Unit): $3000 </li></ul><ul><li>Time Period: Annually </li></ul><ul><li>Annually Break Even: 2,452 units </li></ul><ul><li>Break Even In 1st Year of Sales </li></ul>
  21. 21. Break Even Analysis
  22. 22. VC Funding Total: $14,000,000 $10M $ 7.37 52.63% 1,900,000 VC Phase II $4 M $ 2.963 74.07% 1,350,000 VC Phase I $540,000 $ .54 100% 1,000,000 Initial Valuation Price/Share %Company # Of Shares Round
  23. 23. Thank You

×